{
  "paper_id": "PMC5724237",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724237/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "The study design flow.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/bc2b95f6a51b/bmjopen-2016-015741f01.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/bc2b95f6a51b/bmjopen-2016-015741f01.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/bc2b95f6a51b/bmjopen-2016-015741f01.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/bc2b95f6a51b/bmjopen-2016-015741f01.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/bc2b95f6a51b/bmjopen-2016-015741f01.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5724237/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/bc2b95f6a51b/bmjopen-2016-015741f01.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Formulas for sample size calculations. k=nA/nB is the matching ratio. Φ is the standard normal distribution function. Φ−1 is the standard normal quantile function. α is type I error. β is type II error, meaning 1−β is power. pA=0.352, pB=0.257, α=0.05, β=0.2, κ=1.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/427f2c2fc71a/bmjopen-2016-015741f02.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/427f2c2fc71a/bmjopen-2016-015741f02.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/427f2c2fc71a/bmjopen-2016-015741f02.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/427f2c2fc71a/bmjopen-2016-015741f02.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/427f2c2fc71a/bmjopen-2016-015741f02.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5724237/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fae/5724237/427f2c2fc71a/bmjopen-2016-015741f02.jpg"
    }
  },
  "claims": [
    {
      "sentence": "The criteria are as follows: (1) recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness); typically worse at night/early morning; exacerbated by exercise, viral infection, smoke, dust, pets, mould, dampness, weather changes, laughing, crying or allergens; (2) a high-pitched whistling sound, usually during exhalation, detected in both sides of the lung by auscultation of the chest; (3) symptoms/signs could be relieved automatically or by antiasthmatic treatment; (4) no other diseases that might also cause wheeze, cough, dyspnoea or chest tightness; (5) atypical symptoms/signs without wheeze or whistling sound but fulfilling at least one of the following (a) positive results of bronchial provocation or exercise challenge tests; (b) reversible airflow limitations as follows: (i) the result of bronchial dilation test is positive; (ii) antiasthmatic treatment is effective for the patient; (c) the ratio of daily variation of peak expiratory flow (PEF) is >20%.Inclusion criteria\nPatients will be eligible to participate if all the following criteria apply: (1) male or female outpatient <18 years old, (2) diagnosed with asthma according to the Guidelines for the Diagnosis and Optimal Management of Asthma in Children,8 (3) consent obtained by subject’s parent or guardian and (4) subjects or subject’s caregiver has a smartphone at their disposal.Exclusion criteria\nPatients will not be eligible to participate if any of the following exclusion criteria are present: (1) differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasia or bronchiolitis obliterans; (2) allergy to any inhaler cortical steroid; (3) other diseases that could interfere with the study results judged by the clinicians; (4) participation in any analogous clinical study within 3 months.Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The criteria are as follows: (1) recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness); typically worse at night/early morning; exacerbated by exercise, viral infection, smoke, dust, pets, mould, dampness, weather changes, laughing, crying or allergens; (2) a high-pitched whistling sound, usually during exhalation, detected in both sides of the lung by auscultation of the chest; (3) symptoms/signs could be relieved automatically or by antiasthmatic treatment; (4) no other diseases that might also cause wheeze, cough, dyspnoea or chest tightness; (5) atypical symptoms/signs without wheeze or whistling sound but fulfilling at least one of the following (a) positive results of bronchial provocation or exercise challenge tests; (b) reversible airflow limitations as follows: (i) the result of bronchial dilation test is positive; (ii) antiasthmatic treatment is effective for the patient; (c) the ratio of daily variation of peak expiratory flow (PEF) is >20%.Inclusion criteria\nPatients will be eligible to participate if all the following criteria apply: (1) male or female outpatient <18 years old, (2) diagnosed with asthma according to the Guidelines for the Diagnosis and Optimal Management of Asthma in Children,8 (3) consent obtained by subject’s parent or guardian and (4) subjects or subject’s caregiver has a smartphone at their disposal.Exclusion criteria\nPatients will not be eligible to participate if any of the following exclusion criteria are present: (1) differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasia or bronchiolitis obliterans; (2) allergy to any inhaler cortical steroid; (3) other diseases that could interfere with the study results judged by the clinicians; (4) participation in any analogous clinical study within 3 months.Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The criteria are as follows: (1) recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness); typically worse at night/early morning; exacerbated by exercise, viral infection, smoke, dust, pets, mould, dampness, weather changes, laughing, crying or allergens; (2) a high-pitched whistling sound, usually during exhalation, detected in both sides of the lung by auscultation of the chest; (3) symptoms/signs could be relieved automatically or by antiasthmatic treatment; (4) no other diseases that might also cause wheeze, cough, dyspnoea or chest tightness; (5) atypical symptoms/signs without wheeze or whistling sound but fulfilling at least one of the following (a) positive results of bronchial provocation or exercise challenge tests; (b) reversible airflow limitations as follows: (i) the result of bronchial dilation test is positive; (ii) antiasthmatic treatment is effective for the patient; (c) the ratio of daily variation of peak expiratory flow (PEF) is >20%.Inclusion criteria\nPatients will be eligible to participate if all the following criteria apply: (1) male or female outpatient <18 years old, (2) diagnosed with asthma according to the Guidelines for the Diagnosis and Optimal Management of Asthma in Children,8 (3) consent obtained by subject’s parent or guardian and (4) subjects or subject’s caregiver has a smartphone at their disposal.Exclusion criteria\nPatients will not be eligible to participate if any of the following exclusion criteria are present: (1) differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasia or bronchiolitis obliterans; (2) allergy to any inhaler cortical steroid; (3) other diseases that could interfere with the study results judged by the clinicians; (4) participation in any analogous clinical study within 3 months.Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The criteria are as follows: (1) recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness); typically worse at night/early morning; exacerbated by exercise, viral infection, smoke, dust, pets, mould, dampness, weather changes, laughing, crying or allergens; (2) a high-pitched whistling sound, usually during exhalation, detected in both sides of the lung by auscultation of the chest; (3) symptoms/signs could be relieved automatically or by antiasthmatic treatment; (4) no other diseases that might also cause wheeze, cough, dyspnoea or chest tightness; (5) atypical symptoms/signs without wheeze or whistling sound but fulfilling at least one of the following (a) positive results of bronchial provocation or exercise challenge tests; (b) reversible airflow limitations as follows: (i) the result of bronchial dilation test is positive; (ii) antiasthmatic treatment is effective for the patient; (c) the ratio of daily variation of peak expiratory flow (PEF) is >20%.Inclusion criteria\nPatients will be eligible to participate if all the following criteria apply: (1) male or female outpatient <18 years old, (2) diagnosed with asthma according to the Guidelines for the Diagnosis and Optimal Management of Asthma in Children,8 (3) consent obtained by subject’s parent or guardian and (4) subjects or subject’s caregiver has a smartphone at their disposal.Exclusion criteria\nPatients will not be eligible to participate if any of the following exclusion criteria are present: (1) differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasia or bronchiolitis obliterans; (2) allergy to any inhaler cortical steroid; (3) other diseases that could interfere with the study results judged by the clinicians; (4) participation in any analogous clinical study within 3 months.Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The criteria are as follows: (1) recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness); typically worse at night/early morning; exacerbated by exercise, viral infection, smoke, dust, pets, mould, dampness, weather changes, laughing, crying or allergens; (2) a high-pitched whistling sound, usually during exhalation, detected in both sides of the lung by auscultation of the chest; (3) symptoms/signs could be relieved automatically or by antiasthmatic treatment; (4) no other diseases that might also cause wheeze, cough, dyspnoea or chest tightness; (5) atypical symptoms/signs without wheeze or whistling sound but fulfilling at least one of the following (a) positive results of bronchial provocation or exercise challenge tests; (b) reversible airflow limitations as follows: (i) the result of bronchial dilation test is positive; (ii) antiasthmatic treatment is effective for the patient; (c) the ratio of daily variation of peak expiratory flow (PEF) is >20%.Inclusion criteria\nPatients will be eligible to participate if all the following criteria apply: (1) male or female outpatient <18 years old, (2) diagnosed with asthma according to the Guidelines for the Diagnosis and Optimal Management of Asthma in Children,8 (3) consent obtained by subject’s parent or guardian and (4) subjects or subject’s caregiver has a smartphone at their disposal.Exclusion criteria\nPatients will not be eligible to participate if any of the following exclusion criteria are present: (1) differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasia or bronchiolitis obliterans; (2) allergy to any inhaler cortical steroid; (3) other diseases that could interfere with the study results judged by the clinicians; (4) participation in any analogous clinical study within 3 months.Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The criteria are as follows: (1) recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness); typically worse at night/early morning; exacerbated by exercise, viral infection, smoke, dust, pets, mould, dampness, weather changes, laughing, crying or allergens; (2) a high-pitched whistling sound, usually during exhalation, detected in both sides of the lung by auscultation of the chest; (3) symptoms/signs could be relieved automatically or by antiasthmatic treatment; (4) no other diseases that might also cause wheeze, cough, dyspnoea or chest tightness; (5) atypical symptoms/signs without wheeze or whistling sound but fulfilling at least one of the following (a) positive results of bronchial provocation or exercise challenge tests; (b) reversible airflow limitations as follows: (i) the result of bronchial dilation test is positive; (ii) antiasthmatic treatment is effective for the patient; (c) the ratio of daily variation of peak expiratory flow (PEF) is >20%.Inclusion criteria\nPatients will be eligible to participate if all the following criteria apply: (1) male or female outpatient <18 years old, (2) diagnosed with asthma according to the Guidelines for the Diagnosis and Optimal Management of Asthma in Children,8 (3) consent obtained by subject’s parent or guardian and (4) subjects or subject’s caregiver has a smartphone at their disposal.Exclusion criteria\nPatients will not be eligible to participate if any of the following exclusion criteria are present: (1) differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasia or bronchiolitis obliterans; (2) allergy to any inhaler cortical steroid; (3) other diseases that could interfere with the study results judged by the clinicians; (4) participation in any analogous clinical study within 3 months.Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The criteria are as follows: (1) recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness); typically worse at night/early morning; exacerbated by exercise, viral infection, smoke, dust, pets, mould, dampness, weather changes, laughing, crying or allergens; (2) a high-pitched whistling sound, usually during exhalation, detected in both sides of the lung by auscultation of the chest; (3) symptoms/signs could be relieved automatically or by antiasthmatic treatment; (4) no other diseases that might also cause wheeze, cough, dyspnoea or chest tightness; (5) atypical symptoms/signs without wheeze or whistling sound but fulfilling at least one of the following (a) positive results of bronchial provocation or exercise challenge tests; (b) reversible airflow limitations as follows: (i) the result of bronchial dilation test is positive; (ii) antiasthmatic treatment is effective for the patient; (c) the ratio of daily variation of peak expiratory flow (PEF) is >20%.Inclusion criteria\nPatients will be eligible to participate if all the following criteria apply: (1) male or female outpatient <18 years old, (2) diagnosed with asthma according to the Guidelines for the Diagnosis and Optimal Management of Asthma in Children,8 (3) consent obtained by subject’s parent or guardian and (4) subjects or subject’s caregiver has a smartphone at their disposal.Exclusion criteria\nPatients will not be eligible to participate if any of the following exclusion criteria are present: (1) differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasia or bronchiolitis obliterans; (2) allergy to any inhaler cortical steroid; (3) other diseases that could interfere with the study results judged by the clinicians; (4) participation in any analogous clinical study within 3 months.Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The criteria are as follows: (1) recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness); typically worse at night/early morning; exacerbated by exercise, viral infection, smoke, dust, pets, mould, dampness, weather changes, laughing, crying or allergens; (2) a high-pitched whistling sound, usually during exhalation, detected in both sides of the lung by auscultation of the chest; (3) symptoms/signs could be relieved automatically or by antiasthmatic treatment; (4) no other diseases that might also cause wheeze, cough, dyspnoea or chest tightness; (5) atypical symptoms/signs without wheeze or whistling sound but fulfilling at least one of the following (a) positive results of bronchial provocation or exercise challenge tests; (b) reversible airflow limitations as follows: (i) the result of bronchial dilation test is positive; (ii) antiasthmatic treatment is effective for the patient; (c) the ratio of daily variation of peak expiratory flow (PEF) is >20%.Inclusion criteria\nPatients will be eligible to participate if all the following criteria apply: (1) male or female outpatient <18 years old, (2) diagnosed with asthma according to the Guidelines for the Diagnosis and Optimal Management of Asthma in Children,8 (3) consent obtained by subject’s parent or guardian and (4) subjects or subject’s caregiver has a smartphone at their disposal.Exclusion criteria\nPatients will not be eligible to participate if any of the following exclusion criteria are present: (1) differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasia or bronchiolitis obliterans; (2) allergy to any inhaler cortical steroid; (3) other diseases that could interfere with the study results judged by the clinicians; (4) participation in any analogous clinical study within 3 months.Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The criteria are as follows: (1) recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness); typically worse at night/early morning; exacerbated by exercise, viral infection, smoke, dust, pets, mould, dampness, weather changes, laughing, crying or allergens; (2) a high-pitched whistling sound, usually during exhalation, detected in both sides of the lung by auscultation of the chest; (3) symptoms/signs could be relieved automatically or by antiasthmatic treatment; (4) no other diseases that might also cause wheeze, cough, dyspnoea or chest tightness; (5) atypical symptoms/signs without wheeze or whistling sound but fulfilling at least one of the following (a) positive results of bronchial provocation or exercise challenge tests; (b) reversible airflow limitations as follows: (i) the result of bronchial dilation test is positive; (ii) antiasthmatic treatment is effective for the patient; (c) the ratio of daily variation of peak expiratory flow (PEF) is >20%.Inclusion criteria\nPatients will be eligible to participate if all the following criteria apply: (1) male or female outpatient <18 years old, (2) diagnosed with asthma according to the Guidelines for the Diagnosis and Optimal Management of Asthma in Children,8 (3) consent obtained by subject’s parent or guardian and (4) subjects or subject’s caregiver has a smartphone at their disposal.Exclusion criteria\nPatients will not be eligible to participate if any of the following exclusion criteria are present: (1) differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasia or bronchiolitis obliterans; (2) allergy to any inhaler cortical steroid; (3) other diseases that could interfere with the study results judged by the clinicians; (4) participation in any analogous clinical study within 3 months.Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Study design\nThe study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The study design flow is shown in figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the formulas used to computer sample size.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 22,
    "images_downloaded": 2,
    "tables_filtered": 59
  }
}